Background (chronology and focus of the study)
Development of regenerative medicine using cell-based products that are derived from the processing of human cells and tissues is keenly anticipated in Japan because of difficulties in securing human organs and tissues in our country. With technology breakthroughs and research advances, people are increasingly hopeful that medical technology involving novel cell-based products will develop into new therapies.
At a meeting of the Japanese Council for Science and Technology Policy held in November 2007, opinions were exchanged regarding induced pluripotent stem (iPS) cells, which were attracting considerable attention. The need to encourage and accelerate research on regenerative medicine was voiced. Subsequently, there was a rapid movement towards the realization of new cellular therapies. Thus, action to ensure the smooth and efficient evaluation of products expected in the near future has become necessary.
The utilization of human stem cells, particularly human embryonic stem (ES) cells, in regenerative medicine had been regarded as difficult and has been limited by ethical considerations. However, in the United States, concrete efforts were recently made to test human stem cells in clinical trials. Research into the use of mesenchymal stem cells and induced pluripotent stem (iPS) cells is now conducted around the world. Identifying (at an early stage of development) the technical, medical, and ethical conditions necessary for the utilization of various types of stem cells is vital for their rapid application in patients.
In Japan, there have been 2 main approaches to the research, development, and clinical application of cell-based regenerative medicine. The first one is aimed at the marketing authorization of cell-and tissue-based products under the Japanese Pharmaceutical Affairs Law. In other words, this first approach involves research and development initiated by a company and follows a stepwise process toward evaluation and approval of the product by the relevant regulatory authorities. These steps include 1) regulatory consultation with respect to the quality and safety of a product to ensure that there are no obstacles to its application to human health care in clinical trials, 2) clinical trials, 3) product marketing authorization (manufacturing and import approval), and finally 4) clinical use. When adopting this kind of approach, applicants are encouraged to refer to certain official guidelines, such as Pharmaceutical Notification No. 1314 entitled "Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Manufactured Using Ingredients Derived from Humans and/or Animals," dated December 26, 2000. The second approach is "human stem cell clinical research" conducted, for the time being, according to the Medical Act. This is carried out in accordance with Japanese Ministry of Health, Labour and Welfare Notification No. 0703003, dated July 3, 2006, and entitled "Guideline Concerning Clinical Research Using Human Stem Cells," though the scientific contents are, on the whole, based on the aforementioned Pharmaceutical Notification No. 1314. Revised versions of Notification No. 0703003 were published in November 2010 and October 2013, although the chemistry, manufacturing, and control (CMC) parts therein are based on Japanese Ministry of Health, Labour and Welfare Notifications No. 0208003 and No. 0912006, described later. Whether "human stem cell clinical research" can proceed will depend on deliberations at the Japanese Ministry of Health, Labour and Welfare Scientific Committee Meeting (most reviews are conducted by competent expert committees) and the decision of the Minister of Health, Labour and Welfare. As human stem cell clinical research proceeds, research will be eligible to receive public funding as a "high level/ advanced therapy" if it is determined, from the standpoint of efficacy and safety, to be medical treatment within the public healthcare funding system. It is anticipated that human stem cell clinical research will lead to the smooth development of relevant products by the industry.
The 2006/2007 scientific research group (group leader, Dr. Takao Hayakawa) of the Japanese Ministry of Health, Labour and Welfare inquired into preparing a revised version of "Guideline on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Human Cells and Tissues," which is Appendix 2 in Pharmaceutical Notification No. 1314, mentioned above, in response to requests that Japan should move forward with appropriate regulations for cell-based regenerative medicine by updating standards to reflect rapidly developing science and technology, ethical viewpoints, and international trends. The revised version was originally drafted as a single guideline. However, it was later split into 2 guidelines in order to clarify the specific technical requirements for products derived from autologous cells and allogeneic cells. The autologous-cell guideline, entitled "Guideline on Ensuring the Quality and Safety of Products Derived from the Processing of Autologous Human Cells/Tissue" (Japanese Ministry of Health, Labour and Welfare Notification No. 0208003), was published in February 2008, and the allogeneic-cell guideline, entitled "Guideline on Ensuring the Quality and Safety of Products Derived from the Processing of Allogeneic Human Cells/Tissue" (Japanese Ministry of Health, Labour and Welfare Notification No. 0912006) was published in September 2008. However, the guidelines dealt with autologous-and allogeneic-cell/tissuebased products, respectively, in a general manner. Further studies of critical issues related to the prompt development of products derived from human stem cells, such as human somatic stem cells, human ES cells, and human iPS cells, became necessary.
In the fiscal year 2008, the Japanese Ministry of Health, Labour and Welfare convened a panel of experts: "Study Group on Ensuring the Quality and Safety of Pharmaceuticals and Medical Devices Derived from the Processing of Human Stem Cells." The panel (chaired by Dr. Takao Hayakawa) was established as a scientific research project of the Ministry of Health, Labour and Welfare of Japan.
The objective of the study group is to promote the sound development of products derived from human stem cells by investigating scientific and technological advances, ethics, regulatory rationale, and international trends in human stem cell-derived products and to establish and implement appropriate safety evaluation criteria.
The early activities of the study group (2008e2010) can be summarized as follows:
(i) From the scientific and technological perspective, the group assessed the current state of and future outlook on the manufacture and clinical application of cell-and tissuebased products derived from the processing of human somatic stem cells, human ES cells, and/or human iPS cells, with reference to the most up-to-date research and information. In particular, the group presented the results of the study on sources of human mesenchymal stem cells, the clinical application (including cellular therapy and gene therapy) to many types of diseases, perspectives for the establishment and differentiation of iPS cells and clinical application of iPS cell-based products, and the current state of and views on therapeutic tissue engineering and its practical use in regenerative medicine. (ii) The contents and significance of the existing "Guideline for Clinical Research Using Human Stem Cells" were analyzed, and the appropriateness of the Japanese Ministry of Health, Labour and Welfare's review system for human stem cell clinical research was evaluated. This could lead to proposals of views that should be adopted and future directions that should be followed. (iii) Guidelines and meeting reports were also analyzed, including 2 guidelines published by the Japanese government entitled "Guideline on Ensuring the Quality . Points to be considered include but are not limited to technical details, the manufacturing process, characterization, quality control, stability evaluation, and the data necessary to guarantee the safety and efficacy of the products.
With this perspective in mind and with a desire for consistency in scientific principles and concepts, 2 interim reports on draft guidelines on products derived from the processing of autologous human somatic stem cells and autologous human iPS cells were prepared in 2009, on the basis of Japanese Ministry of Health, Labour and Welfare Notification No. 0208003. Three other interim reports on draft guidelines on products derived from the processing of allogeneic human somatic stem cells, allogeneic human iPS cells, and human ES cells, respectively, were also prepared, on the basis of Japanese Ministry of Health, Labour and Welfare Notification No. 0912006. These 5 sets of draft guidelines were thoroughly discussed from a variety of viewpoints. They were then widely circulated among interested parties as articles in a relevant scientific journal to allow readers to comment (Hayakawa T., et al.: Journal of the Japanese Society for Regenerative Medicine, 9, 116e180 [2010] , in Japanese). Thereafter, these papers were updated and published as 8 articles (Hayakawa T., et al.: Journal of the Japanese Society for Regenerative Medicine, 10, 86e152 [2011] , in Japanese) that served as the basis for the final draft guidelines. After extensive discussions with the study group and after public consultation, the Pharmaceutical and Food Safety Bureau of the Japanese Ministry of Health, Because these official notifications were written in Japanese, we translated them into English in order to introduce them to relevant international societies. The English versions were produced via free translation so that the concepts in the original Japanese versions could be interpreted as precisely as possible.
In this paper, we introduce guidelines that describe the basic technological requirements for ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. There may be cases where certain final products derived from the processing of somatic stem cells that are multipotent and retain the ability to self-replicate may be used in a nonhomologous manner, even if they are autologously derived. In other words, as a result of cell processing, the product could exhibit cell characteristics different from those of the starting cells, and the product might be applied and function at a site (cell environment) different from where the original cells were localized. Concerns related to these points have been added to Notification No. 0208003, which serves as a basis for the present guideline.
Before interpreting and implementing the present guideline, the following should be taken into consideration. The ultimate goal is to provide patients with new therapies that utilize regenerative medicine. The role of the guideline is to present the scientific principles, concepts, ideas, and technical elements that will achieve the specified goal in the most efficient and effective manner possible. Because a wide variety of products is anticipated, encompassing a variety of situations and circumstances, the guideline describes comprehensive points of concern. Therefore, it is important to identify the relevant testing parameters and evaluation methods by taking into consideration, for example, the characteristics of the cells in question, the specific clinical objective, and the method of application. Those that are applicable should be justified and implemented in an appropriate and flexible manner.
Several points should be kept in mind with respect to the development of medicinal products for regenerative medicine and the implementation of this guideline. The desired products are expected to show a potential as a novel therapeutic method as a result of relevant proof of concept (POC) and relevant data and/or information, showing no critical concerns about product safety that might impede the use of the product in humans for the first time. Thorough observance of the Declaration of Helsinki, including proper informed consent and right of self-determination on the part of the patient, is indispensable.
It should be emphasized again that the primary goal of our endeavor is to offer suitable medical opportunities as quickly as possible to patients with severe diseases that are difficult to treat with conventional modalities. The present guideline should be useful for this purpose. Therefore, it is important to interpret and employ the guideline in a flexible and meaningful way. Stringent observance of the guideline without taking into account the patients and their specific situations (which is like putting the cart before the horse) should be avoided.
It is evident that progress in the application of regenerative medicine is desirable for maintaining and improving human health. The development of innovative and revolutionary medicinal products and therapeutic techniques should benefit our country as well as the international community. Regenerative medicine is a great way to make a peaceful international contribution that will be a legacy for mankind. In this context, the role of the government is to promote clinical research and industrialization; regulations and guidelines are adopted such that we advance towards this common goal in a scientific, rational, efficient, and effective manner. All those involved, like players in the same arena with a common goal in mind, accumulating scientific data and concentrating wisdom, should continue to make efforts to deliver these revolutionary cellbased products and therapeutic techniques to patients as soon as possible.
Guidelines on ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells (Notification No. 0907-2, issued by Pharmaceuticals and Food Safety Bureau, Ministry of Health, Labour and Welfare of Japan on September 7, 2012.)
Introduction
1. The present guidelines outline basic technical elements for ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells. These products are hereafter referred to as autologous human somatic stem cell-based products or simply as the "desired cell products." There are many types of cell products and methods of clinical application. In addition, the scientific progress in this field is incessant, while expertise and knowledge are constantly accumulating. Therefore, it is not always appropriate to consider the present guidelines all-inclusive and definitive. Consequently, when testing and evaluating each product, it is necessary to adopt, on a case-by-case basis, a flexible approach based on rationale that reflects the scientific and technological advances at that point in time.
2. The main purpose of evaluating the quality and safety of the desired cell products before conducting investigational clinical trials (e.g., at the time of "clinical trial consultation") is to determine whether there are any quality and/or safety problems that would obviously hinder initiation of human clinical trials of the autologous human somatic stem cell-based products in question, whether certain quality attributes (QA) of the product are understood sufficiently to establish a relationship between the clinical findings and the QA, and whether consistency of the QA can be ensured within a definite range. Simultaneously, it is important to eliminate as much as possible any known risk factors associated with product quality and safety using up-to-date science and technology and to describe the scientific appropriateness of the results of such an action. The remaining presumed risk factors should be weighed against the risks associated with not performing the trials on patients who suffer from diseases that are serious and life-threatening or that involve marked functional impairment or a marked decrease in quality of life (QOL) resulting from the loss of a certain degree of a physical function or form, or for which existing therapies have limitations and do not result in a cure. Furthermore, it is important to entrust the patient with the right to make a decision after receiving all of the available information. When applying for approval of investigational clinical trials, applicants can submit a provisional nonclinical data package, which is prepared rationally by taking into account product aspects and patient aspects including a balance between the risk of the product vs. the risk facing the patient with/without treatment in question, in order to decide to initiate investigational clinical trials, on the premise that the data package submitted at the time of marketing authorization application/registration to ensure quality and safety will be enriched and developed in line with the guidelines as the clinical trial progresses. Finally, applicants are encouraged to discuss with the Pharmaceuticals and Medical Devices Agency (PMDA) the type and amount of data that may be needed to initiate an individual clinical trial. Because of differences in product origin, target disease, target patients, application sites, application methods, and processing methods, there may be numerous variations among individual data packages; these differences cannot be definitively clarified in the present guidelines.
3. The items, test methods, criteria, and any other technical requirements described in the present guidelines are intended to be considered, selected, applied, and evaluated to serve each intended purpose; they do not necessarily require the most stringent level of interpretation and practice. Applicants are encouraged to explain and provide justification for any consideration regarding the background, selection, application, and the content as well as the extent of the evaluation that are appropriate for their own purpose and are scientifically valid.
3. Chapter I. General principles
Objective
The present guidelines outline basic technical elements for ensuring the quality and safety of pharmaceuticals and medical devices derived from the processing of autologous human somatic stem cells (excluding allogeneic somatic stem cells). These products are hereafter referred to as autologous human somatic stem cellbased products or simply as the "desired cell products."
Definitions
The definitions of the technical terms used in this guideline are as follows:
1. "Human somatic stem cells": Cells that are collected from humans or cells that are derived from such cells through cell division and that possess multipotency and maintain the ability to self-renew or a similar ability. washing, sterilization by g-irradiation or other methods, freezing, thawing, and other such procedures that are regarded as minimal manipulations are not considered "processing." 3. "Manufacture": Actions undertaken before the final product (an autologous human somatic stem cell-based product) is released to the market. This includes, in addition to the processing of cells and tissues, minimal manipulations such as separation of a tissue, homogenization of a tissue, separation of cells, isolation of a specific cell, treatment with antibiotics, washing, sterilization by g-irradiation or other methods, freezing, thawing, and other procedures that do not change the original properties of the cells or tissues. 4. "Phenotype": A morphological or physiological characteristic that is produced by certain genes under defined environmental conditions. 5. "Donor": A person who donates his/her own cells or tissue, which serve as a raw material for an autologous human somatic stem cell-based product. For such a product, a patient is definitely a donor. (Note: A patient is identified as a donor for actual treatment. It is also presumed that cells/tissues obtained from a donor other than the patient are used for the purpose of test production during R&D stages.) 6. "Transgenic construct": A construct that contains a vector for introducing a target gene (a specific gene encoding a desired protein or RNA) into a target cell, the target gene itself, and the coding sequences of the elements essential for the expression of the target gene.
Chapter II. Manufacturing methods
Describe all important and relevant information concerning the manufacturing method, taking into account the items listed below. This information will help ensure the quality, safety, and efficacy of the final products, and it is important for guaranteeing consistency in quality from the manufacturing perspective. It should be noted that quality, safety, and consistency are ensured by mutual complementary measures throughout the manufacturing process. It is very important that the measures be rational and that they serve the intended purpose. It is acceptable to omit a portion of the items listed below if the quality, safety, and constancy of the final products can be established by suitably chosen quality tests, control of the final or intermediate products, or control of the manufacturing process.
Raw materials and materials used in manufacturing
1. Human cells and tissues used as raw materials
(1) Features of biological structure and function, selection criteria Provide and explain the reasons for selecting the cells and tissues used as raw materials, with reference to the characteristics of their biological structure and function, such as morphological characteristics, growth characteristics, biochemical indicators, immunological indicators, specific substances produced, and other suitably chosen and appropriate genotype or phenotype indicators (or markers). In particular, demonstrate that the somatic stem cells used as a raw material possess clinically useful stemness. Stemness in this case does not necessarily indicate the potential for multilineage differentiation but refers to the ability to differentiate into cells that have an expected function in vivo. In addition, although demonstrating the differentiation in vitro is desirable, it may suffice to show differentiation in vivo if a rational explanation is provided. For example, when using myocardial stem cells, which are somatic stem cells, as a raw material, it is acceptable to show that myocardial stem cells can differentiate into cardiomyocytes. This should lead to the identification of the main cell characteristics that will be employed when applying cells to the treatment of a patient.
It is acceptable to perform tests using test specimens obtained from a donor other than the patient at the research and development stages before the beginning of a clinical trial. In any case, it is recognized that quantitative limits and technological limits on sample analysis will affect the extent to which such studies can be performed.
(2) Considerations with respect to the donor To ensure the safety of patients, the personnel involved in manufacturing the product, and the healthcare workers who treat patients, establish test parameters by which to assess possible infection of the cells and/or tissues and provide justification for the parameters. Special consideration should be given to hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T-lymphotropic virus (HTLV).
Establish eligibility criteria that take into consideration the genetic characteristics, medical history, and the health condition of the patient among other parameters and provide justification for the use of the patients as donors. Provide any relevant information concerning the noncellular raw materials, taking into consideration their type and characteristics; the form and function in the final product; and evaluation of their quality, safety, and efficacy from the standpoint of the presumed clinical indication. If using materials that are absorbed by the body, perform the necessary tests on the degradation products to address safety concerns.
With respect to the tests that should be carried out, refer to "Basic Views on Biological Tests Necessary for Regulatory Approval for For manufacturing methods for transgenic cells, refer to Chapter 2 and other sections of "Guidelines for Ensuring the Quality and Safety of Gene Therapy Pharmaceuticals," which is an appendix in "Concerning Guidelines for Ensuring the Quality and Safety of Gene Therapy Pharmaceuticals" (hereafter referred to as "Gene Therapy Pharmaceutical Guidelines"), published as Notification No. 1062 by Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare on November 15, 1995. In addition, state the appropriateness of the establishment of a cell line in accordance with the appendix of the same notification.
On the basis of the law (Law No. 97, 2003) implemented to ensure biodiversity by regulating the use (and other aspects) of genetic recombination-derived organisms, a separate application procedure for evaluation will be required when living organisms, including certain cells, "viruses," and "viroids," are genetically modified. The following cells are not regarded as living organisms: "human cells" or "cells that have the ability to differentiate, or differentiated cells that are not viable when alone under natural conditions."
Regardless of the guidelines mentioned above, if a gene introduced into cells is used as a reagent in the manufacturing process and does not contribute either chemically or functionally to the final product, it is acceptable to describe, on the basis of current knowledge, how the quality and safety of the gene conform to the intended use.
Manufacturing process
When manufacturing autologous human somatic stem cellbased products, describe in detail the manufacturing method and verify, to the extent possible, the appropriateness of the method, using the items listed below, in order to maintain consistency in the quality of the product.
Lot control
Indicate whether a lot control procedure is applied for final products and intermediate products. If any lot control is adopted, establish standardized procedures for the makeup and control of the lot, which may include the lot size, labeling/numbering, testing method and acceptance criteria.
Manufacturing method
Provide an outline of the manufacturing method, from the receipt of the cells and tissues to be used as raw materials to the isolation of somatic stem cells and the establishment of the final product. Describe the technical details of the process and necessary process control and product quality control.
(1) Test upon receipt Establish a battery of tests as well as acceptance criteria for assessing the suitability of the cells and tissues that will serve as the raw materials, taking into account the nature of the cells and their intended use. These may include, for example, visual tests, microscopic examination, recovery factors of target cells, cell viability assays, characterization of cells and tissues, and microbiological tests. At the stage of initiating clinical trials, provide the actual measured values obtained up until that point with test samples, and propose a provisional set of acceptance criteria based on these values.
(2) Inactivation and elimination of bacteria, fungi, viruses, and other microorganisms
In cells and tissues that serve as raw materials, inactivate and eliminate bacteria, fungi, viruses, and other microorganisms, if necessary and whenever possible, to the extent possible without changing the cellular characteristics (e.g., cell viability, phenotype, genetic traits, and specific functions) and quality of the cells and tissues serving as raw materials. State the appropriateness of the measures, procedures, and evaluation methods used, if any. Describe the methods used to collect human cells and tissues, to isolate somatic stem cells, and to obtain the cells that serve as the active ingredient in the final product. The items to be described include induction of differentiation, isolation, and culture of the desired cells, preparation of the media, culture conditions, the culture period, and the yield of the cells at each step. Describe the appropriateness of each method.
(5) Establishment of cell banks When a cell bank is established at any stage during the manufacture of autologous human somatic stem cell-based products, describe the rationale for preparing the cell banks; the methods used to prepare the cell banks; the characteristics of the cell banks; and the storage, maintenance, control, and renewal methods as well as any other processes and tests performed. Provide justification for each. Refer to "Derivation and Characterisation of Cell Substrates Used for the Production of Biotechnological/Biological Products" (Pharmaceutical Notification No. 873, issued July 14, 2000, Japanese Ministry of Health, Labour and Welfare) and other documents. However, it is acceptable to omit a portion of the study items, if there is plausible evidence that the cells are of autologous origin.
(6) Measures to prevent erroneous sampling (mix-up) and cross-contamination during the manufacturing process It is extremely important to prevent erroneous sampling and cross-contamination during the manufacturing process when manufacturing the autologous human somatic stem cell-based products. Therefore, describe preventive measures in the process.
Characterization of cells that are a principal component and active ingredient in the final product
For such cells, analyze the attributes, such as cell population purity (to control contamination by nontarget cells), cell viability, morphological characteristics, cell growth characteristics, biochemical markers, immunological markers, distinctive substances produced by the cells, karyotype, and other appropriate genotypic and phenotypic markers. In addition, characterize their biological functions, if necessary. Furthermore, to evaluate the appropriateness of the culture duration and the stability of the cells, use appropriate markers of cell characteristics to demonstrate that there have been no unintended changes in cells cultured longer than the proposed culture period. It is acceptable to perform these studies using test samples obtained from donors who are not patients in place of the products that will be prepared for a clinical trial. On the basis of these test results, identify the critical cell characteristics that should be used when applying the product to a patient. Although comprehensive cell characterization is always desirable, it is not always possible to characterize the cells fully because there are quantitative and technological limits on sample analysis. Thus, it is acceptable to perform a limited study to the extent possible. When cell processing, such as growth within the body, is anticipated after the application, clearly demonstrate the functions expected by describing the specified criteria with respect to the passage number or number of cell divisions.
The form and packaging of the final product
The form and packaging of the final product shall ensure the quality of the final product.
Storage and transport of the final product
If an intermediate or final products need to be stored and transported, the storage procedure and duration, the containers used for transport, and the transportation procedure (including temperature control) shall be stated and their suitability clearly indicated (refer to Chapter III).
Consistency of the manufacturing procedure
To assess the consistency of the manufacturing process using each product (or each lot if any) obtained from different production runs, determine whether they differ significantly with respect to the number of cells, cell viability, and cell characteristics (such as relevant markers of a phenotype and genotype, functional characteristics, and the percentage of the desired cells) and from the point of view of the clinical application method and the intended clinical use of the product. It is acceptable to use test samples obtained from donors who are not patients in place of the products that will be prepared for the clinical trial. Evaluation of intermediate products may provide insight into the suitability of cells and tissues for use as raw materials and the validity of the manufacturing process up until the intermediate-product stage and can provide an appropriate guidepost en route to the final product. Therefore, it may be reasonable to adopt such an approach, where necessary and appropriate.
When the manufacturing process involves long cryopreservation periods or cell cultivation periods, perform sterilization tests at constant intervals to confirm that sterility has been maintained.
Changes in the manufacturing process
If the manufacturing method is altered at some point during development, and the test results that are obtained using products manufactured before the change in the manufacturing method are to be used in the application for clinical-trial or regulatory approval, demonstrate that the products manufactured before and after the change to the manufacturing process are comparable.
Quality control of the final product 4.3.1. Introduction
The overall quality control strategy for products manufactured using human somatic stem cells includes specifications (a set of acceptance criteria and analytical procedures) for the final products, quality control of raw materials for each therapeutic application to each patient, verification of the appropriateness of the manufacturing process, maintenance of consistency, and proper quality control of any intermediate products.
Specifications will differ among final products, depending on the type and properties of the desired cells and tissues, manufacturing methods, intended clinical use, method of clinical application, stability, and test methods. These differences shall be taken into consideration when setting the acceptance criteria and test procedures. In addition, specifications shall be set and justified from the standpoint of achieving the purpose of quality control as a whole, by taking into consideration the mutually complementary relationships among 1) the verification of the suitability of the manufacturing process, 2) the method for maintaining consistency, and 3) quality control of the raw materials and intermediate products. The purpose of the assessment at the initiation of clinical trials is to confirm that the product in question is unlikely to pose significant quality/safety problems for use in investigational clinical trials. Therefore, it is possible to set provisional specifications with allowance for some variation on the basis of the measured values obtained for a few test specimens, as long as one can explain about the relationship between the results of clinical tests and the quality attributes after the clinical trial. However, testing for sterility and the absence of mycoplasma is essential. It should be noted that the quality control strategy, including specifications, should be enriched and developed as the clinical trial progresses.
Quality control of the final product
Refer to the general quality control parameters and tests shown below, set necessary and appropriate specifications for the final product, and provide the rationale for the specifications set.
Set appropriate specifications for individual products that do not make up a lot and for products that do make up a lot because normally each lot is the unit subject to quality control.
(1) Cell number and cell viability For cells that are an active ingredient in the final product, determine the cell number and viability in the final product or, if needed, in an appropriate intermediate product. At the beginning of the clinical trial, it is acceptable to set provisional acceptance criteria that are based on measured values obtained for a small number of test samples.
(2) Tests of identity Confirm that the intended target cells comprise the product by assessing important cell characteristic(s), such as morphological characteristics, biochemical markers, immunological markers, characteristic products, and other appropriate genotypes or phenotypes.
(3) Tests of purity To test the purity of the cell population in a final product, if necessary, set the test parameters, test methods, and acceptance criteria for evaluating and controlling nontarget cells, such as undifferentiated cells, cells that exhibit abnormal growth, transformed cells, and contaminating cells, taking into consideration such parameters as the origin of the target cells and tissues, the culture conditions, other parameters of the manufacturing process, and quality control of intermediate products. At the beginning of the clinical trial, it is acceptable to set provisional acceptance criteria that are based on measured values obtained for a small number of test samples.
(4) Tests for cell-derived, undesirable physiologically active substances Specify appropriate tests for determining the permissible dose limits of any potential undesirable physiologically active substances that are derived from the target cells if the presence of such substances in the product is presumed to clearly affect the safety of the patient. At the beginning of the clinical trial, it is acceptable to set provisional acceptance criteria that are based on measured values obtained for a small number of test samples.
(5) Tests for process-related impurities For substances that may be present in the final product as, for example, contaminants, residues, newly generated products or degradation products; that potentially originate from raw materials, noncellular components, media ingredients (including feeder cells), chemical reagents, or any other process-related materials; and that may have deleterious effects on quality and safety (for example, albumin derived from fetal calf serum and antibiotics), it is necessary to 1) prove that the substance is not present in the final product by taking into consideration the results of process evaluations related to the elimination of the substance or the results of in-process substance control or 2) establish appropriate tests to control permissible levels of the substance in the final product.
When selecting substances to be tested and setting their acceptance criteria, their suitability should be explained and justified. At the beginning of the clinical trial, it is acceptable to set provisional acceptance criteria that are based on measured values obtained for a small number of test samples.
(6) Sterility tests and tests for the absence of mycoplasma Sterility should be ensured throughout the entire manufacturing process by evaluating test samples. The sterility (negative results of tests for common bacteria and fungi) of the final product should be demonstrated before its use in a patient. Appropriate tests confirming the absence of mycoplasma should also be performed. A validated nucleic-acid amplification test can be used. If the results of sterility and other tests on the final product can be obtained only after the product is administered to the patient, methods for dealing with the lack of sterility detected after administration should be established beforehand. In such cases, demonstrate by testing that the intermediate products are sterile and that sterility has been strictly maintained in all processes leading to the final product. If a product from the same facility and same process has already been used in patients, its sterility must be confirmed by testing all patients. If complete closure (hermetic seal) of a product that is a part of a lot has been ensured, tests on representative samples are sufficient. When each different application needs to be tested and if test results can be obtained only after administration to the patient, the decision to administer the product will be based on the most recent data. However, even in such cases, the final product shall be tested.
It is desirable that every effort be made to avoid the use of antibiotics in cell culture systems. However, if antibiotics are used, adopt measures to ensure that they do not influence the sterility tests.
(7) Endotoxin test
Perform the endotoxin test, taking into consideration the impact of the contaminant in the samples. The acceptance criteria do not necessarily depend on the actual measured values. Set acceptance criteria by taking into consideration the safety ranges in the Japanese Pharmacopoeia and/or any other relevant compendia that are based on a single dose of the final product. Endotoxin testing can be established as an in-process control test. However, in such cases, specify the criteria, including the validation results, and provide the justification.
(8) Virus tests
If the absence of HBV, HCV, HIV, and HTLV cannot be demonstrated at the patient level and these viruses could proliferate in the cells, use titer tests to detect viruses and confirm that administration of the stem cell-based products does not adversely affect the patient. This does not apply if the absence of viruses has been demonstrated by testing the cell bank or intermediate products. If components of a biological origin are used in the manufacturing process, it may be necessary to test the final product for viruses originating from those components. However, whenever possible, it is preferable to determine that there is no contamination by testing at the original component stage or by process evaluation.
(9) Specific biological tests
In some instances, it will be necessary to consider specific (quantitative or qualitative) biological testing that takes into account the cell type, intended clinical use, or distinctive characteristics of the cells. At the beginning of the clinical trial, it is acceptable to set provisional acceptance criteria that are based on measured values obtained for a small number of test samples.
(10) Potency assay If a specific physiologically active substance secreted from cells or tissues contributes to the clinical efficacy or effect of an autologous human somatic stem cell-based product, establish test parameters and/or acceptance criteria for the substance in order to demonstrate the intended effect. Set acceptance criteria for potency or quantitation of a gene expression product secreted from the cells when a transgene was introduced. At the beginning of the clinical trial, it is acceptable to set provisional acceptance criteria that are based on measured values obtained for a small number of test samples.
(11) Mechanical compatibility tests For products that require a certain degree of dynamic strength, set acceptance criteria for mechanical compatibility and durability that take into account the site of application. At the beginning of the clinical trial, it is acceptable to set provisional acceptance criteria that are based on measured values obtained for a small number of test samples.
Chapter III. Stability of autologous human somatic stem cell-based products
Taking into full consideration the storage and distribution periods and the storage form, test the cell viability, potency, and other characteristics of autologous human somatic stem cell-based products and/or critical intermediate products to establish storage methods and an expiration date. Provide justification for their suitability. In particular, when product storage and use involves freezing and thawing, confirm that the freezing and thawing processes do not affect the stability or acceptance criteria of the product. Where necessary and possible, conduct stability studies on products whose manufacturing period or storage period exceeds normal periods in order to confirm, to the extent possible, the limits of stability. This does not apply if a product will be used immediately after its production.
If an autologous human somatic stem cell-based product will be transported, the relevant transportation vessels and transportation procedures (such as thermal management) shall be set and their appropriateness justified.
6. Chapter IV. Preclinical safety testing of autologous human somatic stem cell-based products
To the extent that they are scientifically reasonable and technically possible, relevant animal tests and/or in vitro tests may be performed in order to address safety concerns associated with an autologous human somatic stem cell-based product. For noncellular constituents and process-related impurities, safety concerns should be addressed as much as possible by physicochemical analyses not by animal testing.
Testing of human specimens is very valuable, whereas testing the products of human origin in experimental animals does not always yield meaningful results. Thus, there may be a scientific rationale for preparing products of animal origin and testing them in appropriate experimental animals, if such a test system is expected to generate useful results. In such a case, consider using an animal model that is suitable for the target disease. (For example, monkeys may be suitable for studies of neurological diseases, and pigs and/or dogs may be suitable for studies of cardiovascular diseases.) However, because cells with characteristics identical to those of cells that constitute an autologous human somatic stem cell-based product cannot necessarily be obtained from nonhuman animal species, even if the preparation procedures are the same, and because a product of animal cell origin manufactured using identical processes will not necessarily be comparable to a human cell product, applicants should conduct a feasibility study before adopting, conducting, and evaluating such tests. When performing animal experiments using somatic stem cell-based products obtained from nonhuman animal species, explain why extrapolation to humans is appropriate. Depending on the case, consider test systems that employ cells, and clearly explain the suitability of the test system.
Presented below are items and points to consider and to refer to when confirming preclinical safety of a product. These examples are provided for illustration purposes; they are not intended to prescribe tests for which there is no rational basis. Taking into consideration the autologous origin of the cells, the characteristics of the product, the intended clinical use, and other parameters, conduct necessary and appropriate tests, and evaluate and discuss the results in a comprehensive manner.
1. For cells expanded beyond the limit set for routine cultivation (defined by duration of culture, the population doubling level, or the passage number), demonstrate that alterations other than those intended have not occurred. 2. It may be necessary to quantify special physiologically active substances produced by the cells and tissues and to discuss their effects when they are administered to patients. In some cases, significant amounts of active substances including cytokines and growth factors would be produced by the cells, potentially resulting in undesirable effects on the patients. 3. From the standpoint of product safety, examine and discuss the potential effects of the product on a patient's healthy cells and tissues and the consequences. 4. Depending on the type of product, investigate and discuss the possibility of ectopic tissue formation by the cells in the product and the potential safety consequences thereof when the product is administered to the patient. 5. Investigate and discuss the possibility of undesirable immunological reactions caused by the product and/or the expression product of a transgene and the consequences thereof. 6. Discuss in a comprehensive manner the possibility of tumor formation, including benign tumors, and/or malignant transformation, taking into consideration the type and characteristics of the product, number of cells, route of administration, mode of application (e.g., cell sheet or cell suspension), cell engraftment site, target diseases, and suitability of the test systems, among other parameters. If necessary, conduct studies on a suitable animal model. If there is a possibility of tumorigenicity or malignant transformation, provide justification for the use of the product in question, taking into consideration the anticipated efficacy. (Note: For tumorigenicity studies, it is very important to accurately assess tumorigenicity of the final product that will be used in patients. However, tumorigenicity may have to be evaluated using cells from the intermediate product if, for various reasons, such as an insufficient cell number, the cells in the final product cannot be used. Furthermore, when conducting tumorigenicity tests in animal models, variables such as cell dispersion, cell adhesion to scaffolding, cell density, and the administration site may not be the same as those of the final product. The species, strain, and immunological state of the animal may also affect its sensitivity. The tumorigenicity of the final product should be evaluated in a comprehensive manner taking these factors into account.) The risks to the patient arising from tumorigenicity of the final product should be evaluated by weighing the risks of treatment against the benefits of treating the disease. 7. Chapter V. Studies supporting the potency or efficacy of autologous human somatic stem cell-based products 1. A well-designed study with experimental animals and/or cells should be performed to demonstrate, to a scientifically reasonable and technically possible extent, the functional expression, the sustainability of effects, and/or anticipated clinical efficacy (proof of concept) of an autologous human somatic stem cell-based product. 2. For transgenic cells, demonstrate the expression efficiency, sustainability of expression, and biological activity of the desired products derived from the transgene. Discuss the rationale of the transgene expression products as active ingredients for anticipated clinical efficacy (proof of concept) of the autologous human somatic stem cell-based product in question. 3. Where appropriate products derived from the processing of animal somatic stem cells and/or disease model animals are available, use them to study the potential therapeutic efficacy of the product. 4. At the beginning of the clinical trial, detailed experimental studies will not necessarily be required if scientific literature and/or other information supports the prediction that the potency or efficacy of the product in question will be markedly superior to that of a different therapeutic method.
8. Chapter VI. Pharmacokinetics of autologous human somatic stem cell-based products 1. Pharmacokinetic studies of the internal behavior of transgene expression products or cells/tissues that constitute the final products (these studies may include assessment of the absorption and distribution in experimental animals), should be performed to an extent that is technically possible and scientifically valid. Thereby, these experiments are expected to estimate the survival of cells/tissues administered to patients and the duration of their effects, and to determine if the intended efficacy is successfully achieved. (Note: Testing methods may include histological studies, human Alu sequences amplification by polymerase chain reaction (Alu-PCR), magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), and bioimaging.) 2. For autologous human somatic stem cell-based products, clarify, in animal studies, the rationale for the administration method.
In particular, extrapolate from animal experiments the systemic distribution of the cells after systemic administration and discuss the distribution from the point of view of clinical usefulness. (Note: Although it is unclear exactly where the cells adhere with each administration route, local administration is presumed to be preferable to systemic administration. However, if the benefits to patients can be explained, it is acceptable to use systemic administration. In any case, an administration method that minimizes the distribution of a somatic stem cell-based product to organs other than the target organ would be a rational choice. Even if the cells do localize to a site other than the intended transplantation site, this administration method may be used if no adverse effects on patients result. Arrhythmia caused by osteogenesis of mesenchymal stem cells that ectopically localize to the heart is an example of an adverse effect that can result from ectopic differentiation.) 3. When the cells or tissues are directly applied or targeted to a specific site (e.g., tissue) where they are expected to act, clarify the localization, and discuss the effect of the localization on the efficacy and safety of the product.
Chapter VII. Preliminary analysis of clinical trials
The main purpose of the present guideline is to outline points to consider for evaluating the quality and safety of autologous human somatic stem cell-based products, either at the time of application for marketing authorization or at the beginning of an investigational clinical trial. In the latter case, it is necessary to determine, while taking into consideration the clinical usefulness, whether there are any quality and/or safety problems that might impede the initiation of human clinical trials. Thus, quality and nonclinical-safety assessments for the decision to initiate the investigational clinical trials of the product in question should be considered in reference to the points outlined below. Any presumed risk factors associated with product quality and safety should be eliminated, as much as possible, using up-to-date scientific and technological methods, and the scientific appropriateness should be clearly described. Any remaining risks should be weighed against the risks associated with not performing the trials on patients that suffer from diseases that are serious and life-threatening, that involve marked functional impairment or a marked decrease in quality of life (QOL) resulting from the loss of physical function or form, or for which existing therapies have limitations and do not result in a cure. Furthermore, it is necessary to entrust the patient with the right to make a decision after receiving all of the available information, including all information on identified/presumed risks and anticipated benefits.
1. Target disease. 2. Target subjects and patients who should be excluded as participants 3. Details of the therapy to be performed in the subjects, including the application of autologous human somatic stem cell-based products and drugs used concomitantly. (Note: If it is anticipated that drugs will be coadministered in order to maintain, enhance, and/or induce the function of administered or transplanted cells, verify the intended activity of the drugs either in vitro or in vivo.) 4. The rationale for conducting the clinical trials in light of existing therapeutic methods.
5. Plan on explaining the clinical trial to the patients, including the currently known risks and benefits of the product.
Clinical trials should have an appropriate study design and clearly specified endpoints. They should be designed depending on the desired cells/tissues, target disease, and method of application.
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